Yanxuan Wen

Dr. Yanxuan Wen

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2025 in Digestive and Liver Disease
Verified
Journal Article
Closed access
YWYanxuan Wen
Yanxuan Wen
JLJiaxing Li
Jiaxing Li
OMOmar Mukama
Omar Mukama
RHRongqi Huang
Rongqi Huang
SDSihao Deng
Sihao Deng
ZLZhiyuan Li
Zhiyuan Li

23 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
YWYanxuan Wen
Yanxuan Wen
NANouman Amjad
Nouman Amjad
SDSihao Deng
Sihao Deng
HZHaixia Zhang
Haixia Zhang
ZLZhiyuan Li
Zhiyuan Li
Non-alcoholic fatty liver disease (NAFLD) specifically includes the stage of simple fatty liver and the stage of hepatitis. Recent research found mesenchymal stem cell therapy for NAFLD. Mesenchymal stem cells regulate metabolic pathways and energy transport pathways in disease models, reducing the synthesis and utilisation of glucose and fatty acids and restoring the homeostasis of the internal microenvironment. For areas with more severe damage, umbilical cord mesenchymal stem cells (UCMSC) are used for regenerative repair with classic Wnt pathway. The text explores the therapeutic effects of UCMSCs on hepatitis and the surrounding environment from a multifunctional perspective. Mesenchymal stem cells release exosomes in a paracrine manner into the damaged areas of the liver, promoting the differentiation and development of hepatic progenitor cells into hepatocytes, reducing differentiation into cholangiocytes, while assisting hepatic progenitor cells in resisting the progression of inflammation and fibrosis, and promoting the normal function of adaptive immune responses.